论文信息 - Abicipar pegol—a novel anti-VEGF therapy with a long duration of action - 字舞流文

Abicipar pegol—a novel anti-VEGF therapy with a long duration of action

A. Loewenstein | E. Moisseiev

[1] M. Ohji,et al. Evaluation of Abicipar Pegol (an Anti-VEGF DARPin Therapeutic) in Patients With Neovascular Age-Related Macular Degeneration: Studies in Japan and the United States. , 2019, Ophthalmic surgery, lasers & imaging retina.

[2] T. Hohman,et al. Functional Characterization of Abicipar-Pegol, an Anti-VEGF DARPin Therapeutic That Potently Inhibits Angiogenesis and Vascular Permeability. , 2018, Investigative ophthalmology & visual science.

[3] Francisco J. López,et al. Double-Masked, Randomized, Phase 2 Evaluation of Abicipar Pegol (an Anti-VEGF DARPin Therapeutic) in Neovascular Age-Related Macular Degeneration , 2018, Journal of ocular pharmacology and therapeutics : the official journal of the Association for Ocular Pharmacology and Therapeutics.

[4] C. Meyer,et al. Intraocular pharmacokinetics of bevacizumab following a single intravitreal injection in humans , 2012 .